<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58984">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02338128</url>
  </required_header>
  <id_info>
    <org_study_id>FPD2015</org_study_id>
    <nct_id>NCT02338128</nct_id>
  </id_info>
  <brief_title>The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients</brief_title>
  <official_title>The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Febuxostat could protect cardiovascular
      function of peritoneal dialysis patients by lowering serum uric acid.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with more than 3-month-history of peritoneal dialysis and hyperuricemia. Use
      Febuxostat to control their serum uric acid for 1 year. To observe the cardiovascular events
      of patients, and compare and evaluate the changes of heart function, heart construction,
      serum cardiac markers and brain natriuretic peptide (BNP) levels before and after Febuxostat
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cardiovascular events (heart failure, myocardial infarction, unstable angina which need hospitalization，heart surgery, or death caused by cardiovascular disease.)</measure>
    <time_frame>1 year</time_frame>
    <description>heart failure, myocardial infarction, unstable angina which need hospitalization，heart surgery, or death caused by cardiovascular disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum uric acid</measure>
    <time_frame>1st month, 2nd month, 3rd month, 6th month, 9th month, 12th month</time_frame>
    <description>blood test for serum uric acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular function (Heart construction and cardiac ejection fraction determined by echocardiography; blood test: cardiac markers including troponin,myoglobin and creatinine kinase, MB isoenzyme (CK-MB), brain natriuretic peptide)</measure>
    <time_frame>6 months</time_frame>
    <description>Heart construction and cardiac ejection fraction determined by echocardiography; blood test: cardiac markers including troponin,myoglobin and creatinine kinase, MB isoenzyme (CK-MB), brain natriuretic peptide.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Disorders Associated With Peritoneal Dialysis</condition>
  <condition>Hyperuricemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Peritoneal dialysis patients with hyperuricemia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Peritoneal dialysis for more than 3 months with hyperuricemia.

        Exclusion Criteria:

          1. Acute hepatopathy or liver dysfunction (Aspartate transaminase and/or alanine
             aminotransferase exceed 2 times of normal range)

          2. Heart failure (stage IV, NYHA), unstable angina, acute stroke

          3. Severe lung disease or cancer

          4. unable to sign the informed consent form or disagree following-up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ling Wang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Nephrology &amp; Rheumatology, Shanghai Tenth People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology &amp; Rheumatology, Shanghai Tenth People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 5, 2016</lastchanged_date>
  <firstreceived_date>January 9, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Ai Peng</investigator_full_name>
    <investigator_title>Chief of department of Nephrology &amp; Rheumatology</investigator_title>
  </responsible_party>
  <keyword>peritoneal dialysis</keyword>
  <keyword>hyperuricemia</keyword>
  <keyword>cardiovascular</keyword>
  <keyword>Febuxostat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Febuxostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
